Endoscopy 2012; 44(06): 584-589
DOI: 10.1055/s-0032-1306776
Original article
© Georg Thieme Verlag KG Stuttgart · New York

Propofol sedation with bispectral index monitoring is useful for endoscopic submucosal dissection: a randomized prospective phase II clinical trial

T. Sasaki
Department of Gastroenterology, Kitasato University School of Medicine, Kanagawa, Japan
,
S. Tanabe
Department of Gastroenterology, Kitasato University School of Medicine, Kanagawa, Japan
,
M. Azuma
Department of Gastroenterology, Kitasato University School of Medicine, Kanagawa, Japan
,
A. Sato
Department of Gastroenterology, Kitasato University School of Medicine, Kanagawa, Japan
,
A. Naruke
Department of Gastroenterology, Kitasato University School of Medicine, Kanagawa, Japan
,
K. Ishido
Department of Gastroenterology, Kitasato University School of Medicine, Kanagawa, Japan
,
C. Katada
Department of Gastroenterology, Kitasato University School of Medicine, Kanagawa, Japan
,
K. Higuchi
Department of Gastroenterology, Kitasato University School of Medicine, Kanagawa, Japan
,
W. Koizumi
Department of Gastroenterology, Kitasato University School of Medicine, Kanagawa, Japan
› Author Affiliations
Further Information

Publication History

submitted 09 February 2011

accepted after revision 17 January 2012

Publication Date:
25 May 2012 (online)

Background and study aims: Endoscopic submucosal dissection (ESD) has become a standard treatment. However, the treatment time tends to be relatively long and insufflation and manipulation of the endoscope can increase pain and discomfort. We aimed to find an optimal method for sedation during ESD.

Patients and methods: Patients scheduled to undergo ESD for early gastric cancer or adenoma were randomly assigned to sedation with midazolam or propofol, and consciousness level was evaluated by bispectral index (BIS) monitoring. Primary end points of effectiveness (three parameters) and secondary end points of safety during ESD and after return to the ward were compared between the groups. Study registration was in the UMIN Clinical Trial Registry (UMIN 000001497), and the institutional trial number was KDOG 0801.

Results: From June 2008 through June 2009, we enrolled 178 patients (90 midazolam, 88 propofol). Regarding safety after ESD, recovery was significantly better in the propofol group immediately after and at 1 hour and 2 hours after return to the ward (P < 0.001). The number of patients who required a continuous supply of oxygen 2 hours after returning to the ward was significantly lower in the propofol group (midazolam 18; propofol 6; P = 0.010). Though propofol seemed to be better for effectiveness and safety, there were no statistically significant differences for all three primary end points and the safety parameters (hypotension, hypoxia, bradycardia).

Conclusions: Propofol with BIS monitoring improved recovery of patients after ESD, though this study was underpowered to prove the effectiveness and safety of propofol.

 
  • References

  • 1 Ono H, Kondo H, Gotoda T et al. Endoscopic mucosal resection for treatment of early gastric cancer. Gut 2001; 48: 225-229
  • 2 Gotoda T, Iwasaki M, Kusano C et al. Endoscopic resection of early gastric cancer treated by guideline and expanded National Cancer Centre criteria. Br J Surg 2010; 97: 868-871
  • 3 Oda I, Gotoda T, Hamanaka H et al. Endoscopic submucosal dissection for early gastric cancer: technical feasibility, operation time and complications from a large consecutive series. Dig Endosc 2005; 17: 54-58
  • 4 Patel S, Vargo JJ, Khandwala F et al. Deep sedation occurs frequently during elective endoscopy with meperidine and midazolam. Am J Gastroenterology 2005; 100: 2689-2695
  • 5 Riphaus A, Stergiou N, Wehrmann T. Sedation with propofol for routine ERCP in high-risk octogenarians: a randomized, controlled study. Am J Gastroenterol 2005; 100: 1957-1963
  • 6 Agostoni M, Fanti L, Arcidiacono PG et al. Midazolam and pethidine versus propofol and fentanyl patient controlled sedation/analgesia for upper gastrointestinal tract ultrasound endoscopy: a prospective randomized controlled trial. Dig Liver Dis 2007; 39: 1024-1029
  • 7 Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 2nd English edition. Gastric Cancer 1998; 1: 10-24
  • 8 American Society of Anesthesiology. New classification of physical status. Anesthesiology 1963; 24: 111
  • 9 Gotoda T, Yanagisawa A, Sasako M et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer 2000; 3: 219-225
  • 10 Sessler CN, Gosnell MS, Grap MJ et al. The Richmond Agitation–Sedation Scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med 2002; 166: 1338-1344
  • 11 Gan TJ, Glass PS, Windsor A. BIS Utility Study Group et al. Bispectral index monitoring allows faster emergence and improved recovery from propofol, alfentanil, and nitrous oxide anesthesia. Anesthesiology 1997; 87: 808-815
  • 12 Ono H. Early gastric cancer: diagnosis, pathology, treatment techniques and treatment outcomes. Eur J Gastroenterol Hepatol 2006; 18: 863-866
  • 13 Kiriyama S, Gotoda T, Sano H et al. Safe and effective sedation in endoscopic submucosal dissection for early gastric cancer: a randomized comparison between propofol continuous infusion and intermittent midazolam injection. J Gastroenterol 2010; 45: 831-837
  • 14 Fantani L, Agostoni M, Casati A. Target-controlled propofol infusion during monitored anesthesia in patients undergoin ERCP. Gastrointest Endosc 2004; 60: 361-366
  • 15 Cohen LB, Dubovsky AN, Aisenberg J et al. Propofol for endoscopic sedation: A protocol for safe and effective administration by the gastroenterologist. Gastrointest Endosc 2003; 58: 725-732
  • 16 Tohda G, Higashi S, Wakahara S et al. Propofol sedation during endoscopic procedures: safe and effective administration by registered nurses supervised by endoscopists. Endoscopy 2006; 38: 360-367
  • 17 Rex DK, Overley C, Kinser K et al. Safety of propofol administered by registered nurses with gastroenterologist supervision in 2000 endoscopic cases. Am J Gastroenterol 2002; 97: 1159-1163
  • 18 Wehrmann T, Triantafyllou K. Propofol sedation in gastrointestinal endoscopy: a gastroenterologist's perspective. Digestion 2010; 82: 106-109
  • 19 Dumonceau JM, Riphaus A, Aparicio JR et al. European Society of Gastrointestinal Endoscopy, European Society of Gastroenterology and Endoscopy Nurses and Associates, and the European Society of Anaesthesiology Guideline: Non-anesthesiologist administration of propofol for GI endoscopy. Endoscopy 2010; 42: 960-974
  • 20 Vargo JJ, Cohen LB, Rex DK et al. Position statement: nonanesthesiologist administration of propofol for GI endoscopy. Gastrointest Endosc 2009; 70: 1053-1059
  • 21 ASGE Standards of Practice Committee. Guidelines for the use of deep sedation and anesthesia for GI endoscopy. Gastrointest Endosc 2002; 56: 613-617
  • 22 Training Committee, American Society for Gastrointestinal Endoscopy. Training guideline for use of propofol in gastrointestinal endoscopy. Gastrointest Endosc 2004; 60: 167-172
  • 23 Wright SW. Conscious sedation in the emergency department: the value of capnography and pulse oximetry. Ann Emerg Med 1992; 21: 551-555
  • 24 Wehrmann T. Extended monitoring of the sedated patient: bispectral index, Narcotrend and automated responsiveness monitor. Digestion 2010; 82: 90-93
  • 25 Varadarajulu S, Eloubeidi MA, Tamhane A et al. Prospective randomized trial evaluating Ketamine for advanced endoscopic procedures in difficult to sedate patients. Aliment Pharmacol Ther 2007; 25: 987-997